DECEMBER 2017
HEMATOLOGY
--- Content provided by FirstRanker.com ---
PAPER-I
HEM/D/17/48/1
Time: 3 hours
Max. Marks: 100
Attempt all questions in order.
--- Content provided by FirstRanker.com ---
Each question carries 10 marks.
Read the question carefully and answer to the point neatly and legibly.
Do not leave any blank pages between two answers.
Indicate the question number correctly for the answer in the margin space
Answer all the parts of a single question together.
--- Content provided by FirstRanker.com ---
Start the answer to a question on a fresh page or leave adequate space between two answers.
Draw table/diagrams/flowcharts wherever appropriate.
Write short notes on:
- a) Vitamin B12 metabolism 4+3+3
b) Role of Vitamin B12 levels in diagnosis of B12 deficiency and pitfalls--- Content provided by FirstRanker.com ---
c) Clinical manifestations of vitamin B12 deficiency
d) Non-megaloblastic macrocytic anemia and its causes - Hemophilia: 3+4+3
a) Causes of acquired hemophilia
b) Eliciting joint abnormalities--- Content provided by FirstRanker.com ---
c) Prenatal diagnosis of hemophilia - Angiogenesis: 3+4+3
a) Its role in hematologic malignancies
b) Anti-angiogenic drugs in treatment of hematologic malignancies
c) Markers of angiogenesis - AML: 4+3+3
a) Molecular markers affecting prognosis of AML
b) FLT3 Inhibitors
c) AML with related myelodysplasia - CART cells in Pediatric ALL: 4+3+3
--- Content provided by FirstRanker.com ---
a) Role of therapy in Pediatric ALL
b) How are they formed?
c) What lab facilities are required for generating and using CART cells in patients? - Autoimmune hemolytic anemia (AIHA): 4+3+3
a) Management of warm type of AIHA.--- Content provided by FirstRanker.com ---
b) Methods of detection of auto-antibodies against RBC
c) Coomb’s negative auto immune hemolytic anemia - a) Compensation in clinical trials 4+3+3
b) Role of sponsors in clinical trial
c) Salient features of Phase I, II and III clinical trials. - a) Growth factors in normal hematopoiesis 3+4+3
b) Microenvironment in acquired aplastic anemia
c) Hematopoietic stem cell - Minimal residual disease in ALL: 3+4+3
a) What is minimal residual disease?--- Content provided by FirstRanker.com ---
b) How is it detected?
c) How does treatment alter based on MRD? - a) What are T-reg cells and how are they picked up? 4+3+3
b) What is their role in ITP?
c) Describe in brief dendritic cells
--- Content provided by FirstRanker.com ---
--- Content provided by FirstRanker.com ---
--- Content provided by FirstRanker.com ---
POSSESSION/USE OF CELL PHONES OR ANY SUCH ELECTRONIC GADGETS IS NOT PERMITTED INSIDE THE EXAMINATION HALL.
--- Content provided by FirstRanker.com ---
This download link is referred from the post: DNB 2017 Dec Previous Question Papers-(Diplomate of National Board) Under NBE